Prognostic value of DCE-CT-derived blood volume and flow compared to core biopsy microvessel density in patients with metastatic renal cell carcinoma

European Radiology Experimental

Frede Donskov¹  Aska Drljevic-Nielsen²  Christina Stilling³  Patricia Switten Nielsen³  Finn Rasmussen⁴  Jill Rachel Mains⁴  Kennet Thorup⁴  Hans Henrik Torp Madsen⁴ 

[1] Department of Oncology, Aarhus University Hospital (AUH), Palle Juul-Jensens Blvd. 99, 8200, Aarhus N, Denmark;Department of Oncology, Aarhus University Hospital (AUH), Palle Juul-Jensens Blvd. 99, 8200, Aarhus N, Denmark;Department of Radiology, Aarhus University Hospital (AUH), Palle Juul-Jensens Blvd. 99, 8200, Aarhus N, Denmark;Department of Pathology, Aarhus University Hospital (AUH), Palle Juul-Jensen Blvd. 99, 8200, Aarhus N, Denmark;Department of Radiology, Aarhus University Hospital (AUH), Palle Juul-Jensens Blvd. 99, 8200, Aarhus N, Denmark;

关键词: Blood volume;    Carcinoma (renal cell);    Microvascular density;    Prognosis;    Tomography (x-ray computed);   

DOI  :  10.1186/s41747-021-00232-2

来源: Springer

【 摘 要 】

BackgroundAngiogenesis is prominent in metastatic renal cell carcinoma (mRCC). We compared two angiogenesis assessment methods: dynamic contrast-enhanced computed tomography (DCE-CT)-derived blood volume (BV) and blood flow (BF) and core biopsy microvessel density (MVD).MethodsAs planned in DaRenCa Study-1 study, DCE-CT and core biopsy were performed from the same tumour/metastasis at baseline. MVD was assessed by CD34 immunostaining in tumour (CD34-indexT) or tumour including necrosis (CD34-indexTN). BV and BF were assessed using the DCE-CT software. Overall survival (OS) and progression-free survival (PFS) were assessed by Kaplan-Meier analysis. Spearman coefficient (rho) tested the correlation between MVD and BV, BF, or CT density (HU).ResultsAt baseline, 25 patients had analysable scans and tissue. BVdeconv, BVPatlak, and BFdeconv > median were associated with favourable OS (43.2 versus 14.6 months, p = 0.002; 31.6 versus 20.2 months, p = 0.015; and 31.6 versus 24.5 months, p = 0.019). CD34-indexT and CD34-indexTN did not correlate with age (p = 0.543), sex (p = 0.225), treatment (p = 0.848), International mRCC Database Consortium category (p = 0.152), synchronous versus metachronous metastatic disease (p = 0.378), or tumour volume (p = 0.848). CD34-indexT or CD34-indexTN > median was not associated with PFS (p = 0.441 and p = 0.854, respectively) or OS (p = 0.987 and p =0.528, respectively). CD34-indexT or CD34-indexTN was not correlated with BV, BF, or HU (rho 0.20–0.26).ConclusionsDifferently from MVD, DCE-CT-derived BV and BF had prognostic impact and may better reflect angiogenesis in mRCC.Trial registrationNCT01274273

【 授权许可】

CC BY